Business Wire

Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes

Share

Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the transformative work of the EXALT-1 trial, published in Cancer Discovery, by using deep learning algorithms to classify complex cell morphologies in patient cancer tissue samples into disease “morphotypes.”

EXALT-1 was the first prospective trial to demonstrate significantly improved outcomes for late-stage haematological cancer patients using an AI-supported precision medicine platform to guide personalised treatment recommendations as compared to physician’s choice of treatment. In EXALT-1, 40% of patients experienced exceptional responses lasting at least three times longer than expected for their respective disease. The post-hoc analysis published today in Blood Cancer Discovery shows that combining the technology as used in EXALT-1 with new deep learning advancements that take advantage of cell-specific features in high-content images revealed a potential to further increase these patient outcomes.

“Following results of the EXALT-1 study, these findings continue to validate that our AI-guided precision medicine platform has the ability to identify highly actionable clinical treatment recommendations for blood cancers, deepening our insights and enhancing the clinical predictive power of the platform to help patients,” said Gregory Vladimer, Ph.D., VP Translational Research at Exscientia and co-inventor of the platform technology. “Cell morphology, or assessing the characteristics of cells, is fundamental to the diagnosis of cancer. Within this research, we were able to utilise deep learning within the platform to improve our ability to identify personalised cancer treatments, leading to improved clinical outcomes for patients. At Exscientia, we are excited to expand the platform’s applications in order to bring personalised medicine to broader populations.”

“We believe performing drug screens directly in tumour tissues of cancer patients is a great step forward in understanding tumour complexity compared to traditional cell model systems. The fact that we can now harness the power of deep learning to turn these terabytes of images into actionable insights is very exciting indeed,” added Prof. Berend Snijder, Principal Investigator at the Institute of Molecular Systems Biology of the ETH Zurich in Switzerland.

The impact of deep learning on the clinical predictive power of ex vivo drug screening was assessed in a post-hoc analysis of 66 patients over a period of three years in a combined data set of 1.3 billion patient cells across 136 ex vivo tested drugs across haematological diagnoses including acute myeloid leukaemia, T-cell lymphomas, diffuse large B-cell lymphomas, chronic lymphocytic leukaemia and multiple myeloma. Patients receiving treatments that were recommended by the platform’s immunofluorescence analysis or deep learning on cell morphologies showed an increased rate of achievement of exceptional clinical response, defined as a progression free survival period that lasted three times longer than expected for each patient’s respective disease. Post-hoc analyses confirmed that the clinical predictions became more accurate when also considering the drug toxicity on the healthy cells within the tested patient sample.

Exscientia’s precision medicine platform uses custom deep learning and computer vision techniques to extract meaningful single-cell data from high content images of individual patient tissue samples. This analysis generates clinically-relevant insights into which treatments will deliver the most benefit to an individual patient. Further evaluation of individual patient results through Exscientia’s genomics and transcriptomics capabilities may help Exscientia further understand which other patients may benefit from similar treatments. The underlying technology was developed by Dr. Gregory Vladimer and Prof. Berend Snijder while working in the laboratory of Giulio Superti-Furga at the CeMM Research Center for Molecular Medicine in Austria.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements with regard to Exscientia’s expectations with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, preclinical studies and clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its precision medicine platform and AI-driven drug discovery platform. Words such as “anticipates,” "believes," “expects,” "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the uncertainties inherent in predicting future results and conditions, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Sara Sherman
investors@exscientia.ai

Media:
Amanda Galgay
media@exscientia.ai

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Airship Details Speakers for Elevate22, a Global Gathering of Mobile-First CXOs and Business Decision-Makers27.9.2022 13:37:00 CEST | Press release

Mobile app experience company Airship today announced speakers for Elevate22: Mastering MAX, an annual global forum for business leaders striving to create exponential value for both customers and brands through mobile apps. After two years of virtual gatherings, Elevate22 will take place on September 28 in New York City at Glasshouse Chelsea and in London on October 13 at Shoreditch Studios. Brand speakers include executives from Accenture, Bauer Media Group, BBC, Chipper Cash, CNET, DAZN, Disneyland Paris, Forrester Research, Inc., France TV, KeyBank, Kindred Group, Kingfisher plc, NBC Sports, OLIO, PayByPhone, SiriusXM, Southwest Airlines, Studio, YES Network and Zillow Group. Elevate22 programming is designed to both inspire and share proven strategies across the entire mobile app customer lifecycle, from acquiring customers and rethinking how to optimize life after download™, to optimizing the long game and navigating the changing data environment. The event is curated for executi

Aktana and Envision Pharma Group Partner to Help Medical Affairs Navigate the Evolving Physician Engagement Landscape27.9.2022 13:33:00 CEST | Press release

Aktana, the leader in intelligent customer engagement for the life sciences industry, and Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange. By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address HCP demands for personalized, scientifically relevant content and coordinated omnichannel engagement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005291/en/ Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equi

FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific27.9.2022 13:30:00 CEST | Press release

Leading supply chain visibility company FourKites today announces a $10M investment from Mitsui & Co., Ltd. to expand FourKites’ offerings across the APAC region. This investment encompasses the first phase in an ongoing strategic relationship between FourKites and Mitsui, which the two companies intend to formalise by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005141/en/ FourKites Announces $10M Strategic Investment from Mitsui & Co. to Transform Supply Chains in Asia-Pacific (Graphic: Business Wire) Mitsui’s investment in FourKites is the culmination of a yearlong effort between the two companies, which included Mitsui’s extensive due diligence of the supply chain visibility landscape. Given FourKites’ market-leading offerings and proven track record in the region, Mitsui is planning to invest significant resources to expand FourKites’ coverage in APAC, including sales, customer service, oper

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients27.9.2022 13:00:00 CEST | Press release

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities. Forge’s plasmid manufacturing services encompass three grades to accommodate a phase-appropriate approach: Research-Grade, suitable for discovery, research and development; GMP-Pathway, suitable for early-stage clinical trial cGMP AAV manufacturing, and cGMP, suitable for late-stage clinical and commercial cGMP manufacturing. Forge’s plasmid production services utilize single-use systems that seamlessly integrate into the Company’s platform AAV manufacturing process, allowing continuity of manufacturing for clients and streamlined vendor management. Research-Grade and GMP-Pathway plasmid grades are currently available,

DOQMIND Announces Peter Hulsmans as CEO27.9.2022 13:00:00 CEST | Press release

DOQMIND (www.DOQMIND.com), a leading label and artwork management technology provider, announced today that Peter Hulsmans has been appointed CEO. With more than 20 years of label and artwork management leadership experience, Hulsmans brings a high-growth, customer-focused mindset to DOQMIND. “Peter’s experience and extensive industry knowledge make him the right person to build momentum and drive DOQMIND’s aggressive expansion plans,” said Ignace Cosaert, a board member of Athena Graphics, DOQMIND’s founding company. “Peter is known in the industry as someone who always delivers on his customer commitments, aligned with Athena’s reputation for delivering high-quality prepress services since 1991. He will be an excellent steward of our values, products, and brand portfolio.” DOQMIND has been providing label and artwork management technology to some of the most well-known brands for the last 15 years as part of Athena’s product portfolio. Its growth has positioned the company to spin of